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Abstract
Background: One of the most striking features of the childhood malignancy neuroblastoma (NB) is its clinical
heterogeneity. Although there is a great need for better clinical and biological markers to distinguish between
tumours with different severity and to improve treatment, no clear-cut prognostic factors have been found. Also,
no major NB tumour suppressor genes have been identified.
Methods: In this study we performed expression analysis by quantitative real-time PCR (QPCR) on primary NB
tumours divided into two groups, of favourable and unfavourable outcome respectively. Candidate genes were
selected on basis of lower expression in unfavourable tumour types compared to favourables in our microarray
expression analysis. Selected genes were studied in two steps: (1) using TaqMan Low Density Arrays (TLDA)
targeting 89 genes on a set of 12 NB tumour samples, and (2) 12 genes were selected from the TLDA analysis for
verification using individual TaqMan assays in a new set of 13 NB tumour samples.
Results: By TLDA analysis, 81 out of 87 genes were found to be significantly differentially expressed between
groups, of which 14 have previously been reported as having an altered gene expression in NB. In the second
verification round, seven out of 12 transcripts showed significantly lower expression in unfavourable NB tumours,
ATBF1, CACNA2D3, CNTNAP2, FUSIP1, GNB1, SLC35E2, and TFAP2B. The gene that showed the highest fold change
in the TLDA analysis, POU4F2, was investigated for epigenetic changes (CpG methylation) and mutations in order
to explore the cause of the differential expression. Moreover, the fragile site gene CNTNAP2 that showed the
largest fold change in verification group 2 was investigated for structural aberrations by copy number analysis.
However, the analyses of POU4F2 and CNTNAP2 showed no genetic alterations that could explain a lower
expression in unfavourable NB tumours.
Conclusion:  Through two steps of verification, seven transcripts were found to significantly discriminate
between favourable and unfavourable NB tumours. Four of the transcripts, CACNA2D3, GNB1, SLC35E2, and
TFAP2B, have been observed in previous microarray studies, and are in this study independently verified. Our
results suggest these transcripts to be markers of malignancy, which could have a potential usefulness in the clinic.
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Background
Neuroblastoma (NB) is the most common extracranial
solid tumour in children and accounts for around 15% of
all childhood cancer deaths. It is a disease of the sympa-
thetic nervous system and most often arises in the adrenal
glands [1]. The most important prognostic factor in NB is
clinical stage, which is based upon the local disease exten-
sion, degree of resection, and body dissemination [2,3].
Age at diagnosis is also an important factor, the younger
the age the better the outcome, even when the disease is
metastatic [4]. Although there is a number of commonly
occurring genetic changes within the group of disease, no
consensus alterations has been found that could explain
the general pattern of tumourigenesis in these malignan-
cies. Among the most frequent changes, which are also
strongly associated with disease prognosis, are genomic
amplification of MYCN (MNA), deletion of parts of chro-
mosome arm 1p (del1p), partial deletion of 11q (del11q)
and unbalanced gain of 17q. All these aberrations are cor-
related with poor outcome and clinical aggressiveness
while whole chromosome gains or losses, and hyperdip-
loid/near-triploid cells define the more favourable
tumour types [5]. Although the unbalanced chromosomal
alterations affecting 1p, 11q and 17q have been known
for some time, no single candidate gene has been unam-
biguously confirmed despite thorough mapping of these
regions [6]. Recently, mutations of the Anaplastic Lym-
phoma Kinase (ALK) gene located on 2p23 ware found to
be the main cause of familial NB [7]. ALK has also been
found to be altered in sporadic NB tumours through
either mutations (approximately 10%) or amplifications
(approximately 5%) [7-11].
A particular hallmark of NB is its heterogeneity, in which
some tumours regress spontaneously or with limited
treatment while the most aggressive forms, especially in
elder children (>1 year of age), have metastasised already
at the time of diagnosis and are often resistant even to
aggressive multimodal therapy [12]. These facts suggest
divergent genetic mechanisms and pathways through
which low- and high stage tumour types develop. Distin-
guishing tumour types by gene expression profiling has
been a successful approach [13]. Moreover, expression
analysis has already contributed to the finding of new
markers and potential candidate genes that might be
involved in tumour development [14-17]. Also, our group
has identified an unbalanced expression of pro- and anti-
apoptotic transcripts in unfavourable versus favourable
tumours [16]. Since then, whole genome expression stud-
ies have shown differential expression patterns between
different clinical stages [14] and between the biological
groups of unfavourable and favourable tumours [15].
Wang and colleagues stated successful use of unsupervised
hierarchical clustering in discriminating between tumours
classified both according to stage and genetic alterations
such as MNA and del1p. McArdle et al [18] also used hier-
archical clustering and found 31 genes that could distin-
guish tumours on the basis of stage and differentiation.
Moreover, an expression pattern highly correlated to dele-
tion of chromosome 11q was observed. Gene expression
can be affected by large structural genomic alterations,
mutational events, or other inactivating mechanisms such
as epigenetic alterations. Expression analysis of large
genes located in genomic instability regions suggest that
cancer progression is linked to inactivation of different
fragile-site genes [19]. Also, distinct CpG island methyla-
tion patterns have been suggested to characterize different
clinical groups of NB [20,21].
In the present study, we sought potential tumour suppres-
sor genes by exploring gene expression differences
between primary NB tumours with favourable or unfa-
vourable biology from a Swedish patient group. The study
is a verification of the results from a microarray analysis
described previously [22]. In the current study, the
selected transcripts from the microarray analysis were
screened for differential expression by array-based quanti-
tative PCR (QPCR). The data was further verified in a new
set of tumours, and two candidate genes were analysed for
inactivating genetic events.
Methods
Tumour samples
A set of 31 primary NB tumours of different stages was
used in this study, 16 tumours were of favourable (F) biol-
ogy and 15 tumours of unfavourable (UF) biology, see
Table 1. Tumours were staged according to the Interna-
tional Neuroblastoma Staging System [2] and the Interna-
tional Neuroblastoma Risk Group Staging System
(INRGSS) [23]. MNA and del1p status of tumour samples
have been characterized in previous studies ([24,25] and
unpublished data) using FISH analysis and microsatellite
markers. Several of the tumours have also been investi-
gated by Affymetrix 250K SNP array [26] to determine the
MNA, del1p and del11q status (Table 1). Informed con-
sent was obtained from the parents, and the study was
approved by relevant ethics committees (Uppsala Univer-
sity d:nr 89/91, date: 15-05-1991). Tumour cases were
assigned as favourable if staged 1–3 or 4S (according to
INSS) with no MNA, del1p, or del11q, and no evidence of
disease at last follow up. Tumour from a patient either
dead of disease, with advanced stage of disease (stage 4)
or with a stage 3 tumour (according to INSS) with either
MNA, del1p, or del11q was classified as unfavourable.
The treatment of the two cases with INSS stage 3 assigned
as favourables (i.e. case 12E8 and 15E5) was as follows:
case 12E8 was treated with non radical surgery only, and
case 15E3 was treated with six courses of chemotherapyBMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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Table 1: Clinical data concerning primary neuroblastomas used in this study
Group Case INSS  INRGSS Age Outcome Ploidy MNA 1p del 11q del 17q gain OS Ver. Group Seq CNA
F 23R4 1 L 105 1 x
14E6MA 1L 2 0 1 n i
18E8 1 L WCG 169 1 x
31R8 1 L A 73 1
35R8 1 L I 50 1
26R9 1 L 91 2
16E1 1 L I 2n 190 2
37R6 1 L 37 2
20R9 2 L 2n nd nd 113 1 x
33R7 2 L nd nd 62 1 x
25R9 2 L A2 n 95 2
10R6 2 L 2n nd nd nd nd 160 2
13E8 2 L A 202 2
12E8MA 3L 2n WCG 209 0
15E3MA 3 L Gain UB WCG 195 0
21R6 4S MS 2n 111 2
UF 19R6 3 L DOD 2n y y y 81x
16R4MA 3L Ayy 131 0 x
9R9 3 M AD O D 2 n y y y 21 1 x x
10R8 3 L AD O D 2 n y y y 59 2 x
10R2MA 4M I DOD 2n y y y 12 0
15R3MA 4M AD O D 2 n y nd y 90x
12E6 4 M AD O D 2 n y nd (y) 9 1
13R0 4 M AD O D 2 n y y y 10 1
26R8 4 M I DOD 2n y y nd nd 18 1
29R2 4 M I 2n y y nd nd 85 1
11E1 4 M A2 n y y 218 2 x
26R0 4 M A2 n Gain yy y 93 2
34R0 4 M AD O D 2 n y 11 2 x
39R1 ? M I 2n y y y 29 2 x
12E3 4 M I DOD 2n y y y 42 x
Column 1: Group, F = Favourable, UF = unfavourable; column 2: Case ID, MA = Cases used in the Microarray study; column 3: Clinical stage 
according to International Neuroblastoma Staging System (INSS) [2]; column 4: Clinical stage according to International Neuroblastoma Risk Group 
Staging System (INRGSS) [23], L = locoregional tumors, M = metastatic tumors, MS = metastases are confined to the skin, liver, and/or bone 
marrow in children younger than 18 months of age.; column 5: Age = Age at diagnosis, B = Below 12 months, I = Intermediate, i.e. 12–24 months, 
A = Above 24 months; column 6: Outcome: DOD = Dead of disease, nd = not determined; column 7: Ploidy: 2n = Diploidy; column 8: MNA = 
MYCN amplification, y = MNA, gain = MYCN< 4 times the ploidy; column 9: 1p del = 1p deletion, y = 1p del, UB = unbalanced; column 10: 11q del 
= 11q deletion, y = 11q del; column 11: y = 17q gain, WCG = whole chromosome gain, (y) = uncertain results; column 12: Overall survival (OS) in 
months; column 13: Verification groups (Ver.Group) with QPCR, 0 = Replicate group, 1 = Verification group 1, 2 = Verification group 2, ni = not 
included; column 14: Seq = Cases used for DNA Sequencing or Bisulphite Sequencing PCR (BSP) of POU4F2; column 15: CNA = Cases used for 
Copy Number Aberration analysis of CNTNAP2.BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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and uneventful radical surgery. Both patients show no evi-
dence of disease, and have been followed up 17 years
from diagnosis (until 1st of January, 2009).
DNA/RNA extraction and cDNA synthesis
DNA was extracted using the DNeasy Blood- and Tissue
kit (Qiagen, Hilden, Germany). RNA was extracted from
collected tumour material after homogenisation by Tis-
sueLyser (Qiagen), using the Totally RNA kit (Ambion, St.
Austin, TX). Genomic DNA was removed with the DNA-
free kit (Ambion) and the purity and integrity of the RNA
were assayed with the ND-1000 spectrophotometer
(Saveen Werner AB, Malmö, Sweden) and RNA 6000
Nano Bioanalyzer (Agilent, Palo Alto, CA) respectively.
Reverse transcription of total RNA was performed using
High Capacity cDNA RT kit (Applied Biosystems, Foster
City, CA), each reaction containing 1 μg RNA, 1× RT
buffer, 4 mM dNTP mix, 1× random primers, 50 U reverse
transcriptase and 20 U RNase inhibitor in a total volume
of 20 μl. The reverse transcription reactions were run
under the following conditions: 25°C for 10 min, 37°C
for 120 min and 85°C for 5 seconds.
Study design and selection criteria
Twelve tumours, six favourable and six unfavourable
tumours were used for the verification of our previous
microarray data [22] by TaqMan Low Density Array
(TLDA), see Verification Group 1 in Table 1. A new set of
tumours, seven favourable and six unfavourable tumours
were used for verification of TLDA data using individual
TaqMan assays (Verification Group 2, Table 1). The selec-
tion of tumour samples for verification groups was ran-
dom and no tumours were analysed in both verification
experiments. The NB cell line SK-N-AS was used as a cali-
brator control to allow comparison of expression data
between runs. The study design is illustrated in Figure 1.
The expression levels in five out of six tumours included
in the microarray expression analysis (marked "MA" in
Table 1) were confirmed by technical replication in the
TLDA analysis of 89 transcripts. The material from the
sixth tumour 14E6 was limited and was therefore
excluded from the TLDA technical replicate study. The ini-
tial microarray data is publicly available on ArrayExpress
http://www.ebi.ac.uk/microarray-as/ae/, accession: E-
MEXP-2250.
From the microarray study, transcripts were selected by
the following criteria: i, probe sets with a fold change >2,
ranked after significance level (p = 0,1E-05 to 0,05; calcu-
lated by ttest, [22]), ii, lower expression in unfavourable
compared to favourable tumours. Transcripts represented
by more than one probe set were included only when the
majority of the probe sets showed a fold change >2. These
stringent criteria resulted in a list of 88 transcripts. The
PHOX2B gene was found on position 198 in the gene list,
but due to its known involvement in NB it was also
selected for the TLDA analysis. The first verification of 89
transcripts was analysed and the results guided the selec-
tion of twelve genes to be validated in verification group
2 (Table 1, Figure 1). These genes were selected only if sig-
nificant (p < 0,05) and fulfilling one of two criteria: i,
among the top ten genes with the highest fold change, ii,
suggested to discriminate between groups in previous NB
expression studies. In addition, one gene, ATBF1, was
selected since it was the most significant and also previ-
ously reported to be involved in prostate and breast can-
cer. Another gene, FUSIP1, was selected due to its
localization at chromosome arm 1p36. Four genes fulfill-
ing criteria ii are parts of the noradrenic biosynthesis path-
way and are described in detail elsewhere [22], and were
not included in the second verification round.
Real-time quantitative PCR (QPCR)
A total number of 17 NB tumours were investigated for 89
genes of interest and three endogenous controls, i.e. ADA,
GUSB and GAPDH. The selection the endogenous con-
Schematic representation of the study approach Figure 1
Schematic representation of the study approach. Ver-
ification group1: Eighty-nine genes were selected for gene 
expression analysis using TaqMan Low Density Array, TLDA, 
see text for details. In the TLDA analysis, six favourable (F) 
and six unfavourable (UF) tumours were included. Verifica-
tion group 2: Twelve candidate genes were selected for vali-
dation by TaqMan individual QPCR, TM (see Table 3 for 
selection criteria). A new, randomly selected set of favoura-
ble (n = 7) and unfavourable (n= 6) tumours were used in the 
analyses, and all samples were run in duplicates (×2).BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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trols is described in detail in Wilzén et al [22]. Custom-
designed TLDA cards containing 95 individual assays were
ordered from Applied Biosystems http://www.appliedbio
systems.com. Three samples and one calibrator (SK-N-AS)
were loaded to each card according to manufacturer's
instructions, each reservoir containing 83 ng of RNA con-
verted to cDNA in a total volume of 100 μl. Twelve
selected transcripts from the TLDA analysis were reana-
lysed with individual TaqMan assays in a new set of 12
tumours. The identical TaqMan assays as present on the
TLDA cards were ordered separately from Applied Biosys-
tems for the the second verification study. Individual
QPCR reactions were set up in duplicates in 384 well
plates using the Biomek FX pipetting robot (Beckman
Coulter) and were carried out in 10 μl reactions with 1×
TaqMan® Gene Expression Mastermix (Applied Biosys-
tems), 1× Gene-specific assay and 7,5 ng RNA converted
into cDNA. Both TLDA cards and individual QPCR plates
were run and analysed by the ABI PRISM®  7900HT
Sequence Detection System (SDS 2.2, Applied Biosys-
tems) according to manufacturer's protocol (Applied Bio-
systems).
Expression data analysis
Calculations were performed using the ΔΔCt relative
quantification method. The thresholds and baselines were
set manually in SDS and Ct values were extracted. All Ct
values were normalized to the mean of the endogenous
controls  ADA,  GUSB, and GAPDH  for each sample
[22,27]. To evaluate the agreement between the microar-
ray and QPCR expression levels in the technical replicate,
a Pearson correlation coefficient was calculated for each
gene.
Fold change between groups was calculated from the
means of the logarithmic expression values. To be able to
compare results between runs, all expression values were
calibrated to the expression values of the NB cell line SK-
N-AS, which was included in every real-time QPCR run.
To confirm that the differences in expression were indeed
representative for the two groups, a one-tailed, hetero-
scedastic student's t-test was performed for every tran-
script.
The final estimation of fold change and significance was
based on the last verification group to avoid effect bias.
Sequencing analysis
DNA sequencing analysis of the gene POU4F2 [GenBank:
NM_004575] was performed on four favourable and four
unfavourable primary tumours showing the lowest and
highest expression values in their respective group (Table
1). Sixteen PCR-primer pairs covering the promoter
region and the coding regions of POU4F2 were designed
using Exon Primer http://ihg.gsf.de/ihg/ExonPrimer.html
and purchased from Invitrogen (Invitrogen, Carlsbad,
CA). Of these, four pairs span the 5'UTR/promoter region
including one covering the Wilms' tumour transcription
factor (Wt1) binding site located at -1387 to -1377 from
translation start (Figure 2) [28]. Exon 1 was covered by
three amplicons and exon 2 of nine amplicons (Figure 2).
Primer sequences are available on request. Touch down
(TD) PCR was performed in 10 μl reactions containing 1×
Coral Load PCR Buffer (Qiagen), 20 mM dNTP mix, 1× Q-
solution (Qiagen), 0,25 U Hot Star TaqPlus DNA
polymerase (Qiagen), 10 μM of forward (FWD) and
reverse (REV) primer, respectively, and 50 ng of tumour
DNA. The TD PCR program was optimized for GC-rich
fragments and run at 95°C for 15 min before cycling 20
rounds of 98°C for 30 sec, 60°C for 30 sec (decreasing
0,5°C in every cycle), and 72°C for one minute – fol-
lowed by 25 cycles of 98°C for 30 sec, 50°C for 30 sec and
72°C for 1 min and finally a 72°C extension step for 7
minutes. Amplification products were analysed for specif-
Schematic representation of the POU4F2 gene Figure 2
Schematic representation of the POU4F2 gene. Green lines represent exons where the green boxes specify the protein 
coding parts. Position 1 marks the translation start. The upper grey lines represent the fragments amplified by selected primer 
pairs. The lower dark blue box indicates predicted CpG islands http://genome.ucsc.edu and the upper blue line marks the 
region covered by methylation analysis.BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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icity on a 2% agarose gel before they were purified using
AMPure magnetic beads (Agencourt Bioscience Corpora-
tion, Beverly, MA) using the Biomek NX pipetting robot
(Beckman Coulter) and eluted in dH2O. Sequencing PCR
was performed using the BigDye Terminator (BDT) v3.1
Cycle Sequence Kit (Applied Biosystems) in 10 μl reac-
tions containing 6 μl 1:3 diluted PCR-template DNA, 1 μl
BDT, 1× BDT buffer and 1,6 μM of the PCR primer, either
FWD or REV. Sequence PCR was run under following con-
ditions; 94°C for 3 min, followed by 50 cycles of 96°C for
30 sec, 50°C for 10 sec and 60°C for 3 min each. Sequenc-
ing products were cleaned using CleanSeq magnetic beads
(Agencourt) using the Biomek NX and resuspended in 10
μl of High Dye formamide (Applied Biosystems). The
sequencing products were separated with gel electro-
phoresis on the 3730 DNA analyser (Applied Biosystems)
and the output data were viewed and analysed using soft-
wares Sequencing Analysis v 5.0 and SeqScape v 2.5, both
from Applied Biosystems. All eight primary tumours and
the positive reference CEPH DNA (CEPH1347-02,
Applied Biosystems) were successfully sequenced. Each
finding was validated by a second PCR and sequencing
reaction.
Bisulphite sequencing
Bisulphite sequencing PCR (BSP) was performed on the
same eight primary tumours as described in the "Sequenc-
ing analysis" section (see above), as well as two NB cell
lines SK-N-AS and SK-N-BE (Table 1). Bisulphite modifi-
cation (BSM) of DNA was performed as described previ-
ously [21]. Prediction of the CpG islands within the
POU4F2  promoter was performed with CpGproD and
CpG island searcher http://cpgislands.usc.edu/ using the
following criteria; an observed to expected CpG ratio over
0,65 and a GC content of over 55% in a stretch longer
than 500 bp as described in Takai et al. [29]. Primers were
designed using Bisearch http://bisearch.enzim.hu/[30].
Amplification of this region was performed with TD PCR
(primer sequences available on request) according to the
same procedures as previously described in the DNA
amplification step of the sequencing experiment (see
above). The amplification was repeated with an inner for-
ward primer (semi-nested PCR) before purifying and
sequencing of PCR products according to previously
described procedures. Two amplicons of different length
but starting with the same forward primer were
sequenced. The shortest of the final amplification prod-
ucts covered 656 bp of the POU4F2 promoter (located at
-655 to +1 from translation start, Figure 2).
Copy Number Aberration (CNA) analysis
CNA analysis of the gene CNTNAP2  [GenBank:
NM_014141] was performed using Single Nucleotide Pol-
ymorphism (SNP) microarrays from six primary tumours
(see Table 1). The SNP microarray experiments have been
described previously [26]. Briefly, Affymetrix 250 K SNP
arrays (Nsp) were used and primary data analysis was per-
formed using GDAS (GeneChip® DNA Analysis software;
Affymetrix), whereas further statistical studies were per-
formed using CNAG (Copy Number Analyzer for Affyme-
trix GeneChip Mapping arrays software, version 3.0;
Genome Laboratory, Tokyo University, http://
www.genome.umin.jp).
Results
QPCR expression analysis
Verification group 1
By TLDA analysis, the differential expressions of 81 out of
87 transcripts were significantly verified (Table 2). Two
transcripts, ITGAE and MGC12760, showed undetectable
expression values and were excluded from the study. A
Pearson correlation calculation of expression values from
the five technical replicates showed a good correlation
between microarray and TLDA expression levels (average
correlation coefficient = 0,7; see additional file 1). The
transcript discriminating groups with the largest fold
change in verification group 1 was POU4F2  (Table 2),
showing an expression level of more than 1500 times
lower (p = 0,011) in the unfavourable tumours compared
to the favourable ones. Five tumours (4/5 unfavourable),
did not express this gene at all (i.e. 25R9, 19R6, 9R9,
10R2, and 15R3). This absence of expression was verified
in three rounds of individual QPCR runs, and the Ct-val-
ues were set to 40 in these cases to enable calculations.
Verification group 2
Twelve significantly differentially expressed transcripts
from the TLDA study were selected for a second verifica-
tion in 13 new tumour samples using individual TaqMan
assays (with primers and probes targeting the same region
as in the TLDA study). For seletion criteria and results see
Table 3. Seven out of 12 genes could be significantly veri-
fied in this second round: ATBF1,  CACNA2D3,
CNTNAP2, FUSIP1, GNB1, SLC35E2, and TFAP2B (p <
0,05; Table 3 and Figure 3). The three transcripts,
CACNA2D3, CNTNAP2 and TFAP2B, showed a 4–5 times
lower expression in unfavourable tumour types (Figure
3).
In order to test for potential influence of MNA, the 89
genes of the first verification round was compared to two
curated MYC genesets, i.e.
"MYC_ONCOGENIC_SIGNATURE" (212 genes) and
"MYC_TARGETS" (42 genes), from Molecular Signatures
Database at Broad Institute http://www.broad.mit.edu.
None of the 89 genes overlapped with these two genesets.
Moreover, a multiple linear regression study was per-
formed on the 12 transcripts. The analysis showed that
"group" (UF or F) remained the strongest predictor of dif-
ferential expression compared to "MNA" (data notBMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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Table 2: QPCR results of verification group 1
Gene Cytoband t-test  Sign.  FC Earlier suggested by
ACD 16q22.1 0.1029 n.s. 4
ACP1 2p25 0.0023 ** 4
ATBF1 16q22.3 1.70E-05 *** 9
BRSK2 11p15.5 2.40E-04 *** 21
C2orf25 2q23.3 0.0929 n.s. 3
C5orf13 5q22.1 0.0102 * 4
CACNA2D3 3p21.1 0.0019 ** 133 [31]
CBFB 16q22.1 2.04E-05 *** 9
CCND1 11q13 0.0012 ** 6
CDC5L 6p21 0.0072 ** 15
CHCHD2 7p11.2 0.0041 ** 4
CLASP1 2q14.2-q14.3 0.0021 ** 12
CNTNAP2 7q35-q36 0.0011 ** 287
CXXC4 4q24 0.0350 * 10
DBH 9q34 0.0039 ** 15 [15,32]
DCUN1D2 13q34 0.0027 ** 26
DCX Xq22.3-q23 0.0091 ** 9
DDC 7p11 0.0156 * 24 [32,33]
DGUOK 2p13 0.0047 ** 10
DPYSL3 5q32 0.0100 ** 23 [33]
EIF2S3 Xp22.11 0.0024 ** 4
FLJ20323 7p21.3 0.0015 ** 10
FSCN1 7p22 0.0091 ** 4
FSD1 19p13.3 0.0077 ** 8
FUS 16p11.2 0.0350 * 15
FUSIP1 1p36.11 0.0128 * 22
GATA2 3q21.3 0.0260 * 4 [32]
GATA3 10p15 0.0018 ** 6 [15]
GDF1; LASS1 19p12 0.0409 * 10
GNB1 1p36.33 0.0028 ** 10 [15,32]
H3F3B 1q41 0.0057 ** 4
HDAC2 6q21 0.0036 ** 11
HNRPDL 4q21.22 0.0025 ** 7
HNRPH3 10q22 0.0086 ** 7
IDH2 15q26.1 0.0023 ** 6
ILF2 1q21.3 0.0161 * 6
ISL1 5q11.2 0.0074 ** 6
ITGAE 17p13 n.d. n.d. n.d.
KIAA0408 6q22.33 3.96E-04 *** 15
KIDINS220 2p24 0.0014 ** 15
LOC440434 17q12 0.0264 * 11
MAOA Xp11.3 0.0105 * 12
MARCKSL1 1p35.1 0.0107 * 5
MCM6 2q21 0.0301 * 5
MCG12760 1p36.13 n.d. n.d. n.d.
MCG4655 16q22.1 0.3849 n.s. 1
MTF2 1p22.1 7.83E-04 *** 10
NACA 12q13.3 0.0240 * 4
NDUFS4 5q11.1 5.06E-04 *** 5
NONO Xq13.1 0.0015 ** 6
NSUN6 10p12.31 0.0010 *** 20
PAFAH1B3 19q13.1 0.0044 ** 8
PALM 19p13.3 2.28E-04 *** 7
PHOX2A 11q13.2 0.0223 * 26
PHOX2B 4p12 0.0042 ** 18 [15]
PILRB 7q22.1 0.0084 ** 15
PKIA 8q21.11 8.69E-04 *** 21
POU2F1 1q24.1-24.2 5.77E-04 *** 20
POU4F2 4q31.2 0.0106 * 1518 [18,34]BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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shown), which indicate that the altered expression levels
of these transcripts are not a secondary effect of MNA.
POU4F2 sequencing
To find out whether the dramatic expression variation of
POU4F2 could be explained by differences at the genomic
sequence we screened the promoter and coding parts of
the gene for mutations by DNA sequencing in eight NB
tumours (Table 1). The coding regions were void of muta-
tions, neither did the Wt1 binding site nor the rest of the
sequenced 5'UTR show any alterations compared the ref-
erence sequence. In two of the tumours, the 3'UTR also
PRKRA 2q31.2 0.0042 ** 18
RABL2B; RABL2A 2q13 0.0122 * 17
RAPGEF6 5q23.3 0.0097 ** 37 [35]
REV1L 2q11.2 8.99E-04 *** 9
RPL19 17q12 0.1034 n.s. 2
SEC61G 7p11.2 0.0140 * 7
SEPHS1 10p14 4.51E-04 *** 6
SFRS3 6p21 0.0126 * 5
SHC1 1q21 0.0129 * 12
SLC18A1 8p21.3 0.0130 * 25
SLC35E2 1p36.33 0.0241 * 3 [15]
SLC6A2 16q12.2 0.0012 ** 540
SMN1; SMN2 5q13 0.0104 * 8
SMPD4 2q21.1 0.0279 * 6
SPAST 2p22.3 2.48E-05 *** 9
ST13 22q13.2 0.0324 * 5
TAF9B Xq21.1 0.0243 * 7
TCP1 6q25.3 2.89E-04 *** 6
TFAP2B 6p12.3 0.0115 * 13 [14,31,33,34]
TH 11p15.5 0.0126 * 11 [15,32]
TIA1 2p14 5.99E-05 *** 16
TMSL8 Xq22.1 0.2105 n.s. 2
TNFRSF25 1p36.31 0.0717 n.s. 8 [15,33,36]
TOP2B 3p24.2 2.49E-04 *** 4
TPRKB 2p13.2 0.0386 * 4
UBE2E3 2q31.3 0.0110 * 13
UCKL1 20q13.33 0.0013 ** 11
VPS28 8q24.3 0.0090 ** 9
XRCC5 2q35 0.0092 ** 7
YWHAQ 2p25.1 0.0400 * 5
Ver 1 = verification group 1; Cytoband = Chromosomal location; t-test = significance by Student's t-test; n.d. = not determined; Sign. = Significance 
level by Student's t-test, * p < 0,05, ** p < 0,01, *** p < 0,001, n.s. = not significant; FC = Fold change between groups. Transcripts selected for the 
second verification are highlighted in bold.
Table 2: QPCR results of verification group 1 (Continued)
Table 3: QPCR results of genes selected for the second verifiaction round
Gene Selection criteria FC Ver 1 t-test Ver 1 FC Ver 2 t-test Ver 2
ATBF1 p-value 9 1.70E-05 2.7 0.032
CACNA2D3 FC 133 0.0019 5.1 0.049
CNTNAP2 FC 287 0.0011 5.1 0.0036
DCUN1D2 FC 26 0.0027 1.0 0.46
DPYSL3 FC 23 0.01 1.6 0.19
FUSIP1 LOH 22 0.013 2.0 0.013
GNB1 PR 10 0.0028 2.3 0.007
POU4F2 PR; FC 1518 0.011 3.7 0.15
RAPGEF6 PR 37 0.0097 1.2 0.36
SLC35E2 PR 3 0.024 3.5 0.011
SLC6A2 FC 540 0.0012 2.8 0.11
TFAP2B PR 13 0.012 4.5 0.0049
Column 2: p-value = Most significant in Ver 1 and cancer involvement, FC = Top ten with highest fold change (FC), LOH = Localized in a common 
Loss of Heterozygosity (LOH) region, PR = Previously Reported in NB microarray expression studies; column 3–4: Ver 1 = verification group 1; 
column 5–6: Ver 2 = verification group 2;BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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Fold scatter plot of 12 transcripts studied by both TLDA and TaqMan Figure 3
Fold scatter plot of 12 transcripts studied by both TLDA and TaqMan. The geometric means of the relative expres-
sion in favourable tumours of verification group 2 are used as reference (Fold = 1). Open squares = technical replicate group 
studied by TLDA but also represented on the microarray; Open circles = verification group 1 studied only with TLDA; Filled 
triangles = verification group 2 studied by individual TaqMan assays. The fold change (FC) between groups is based on expres-
sion values in verification group 2. Group: F = Favourable tumour types: Group UF = Unfavourable tumour types.BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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contained a known polymorphism, SNP rs 7669891, for
which one of the tumours was homozygous and the other
heterozygous (data not shown).
POU4F2 methylation analysis
Our other approach to find possible explanations for the
differences in regulation of POU4F2 was to test whether
the gene was epigenetically altered by promoter methyla-
tion. Preliminary results from methylation studies per-
formed by our group indicate that the expression of
POU4F2 increases in NB cell lines treated with a demeth-
ylating agent in conjunction with a histone deacetylase
inhibitor (Carén et al, manuscript in preparation). DNA
from the four unfavourables with the lowest expression
and the four favourables with the highest expression of
POU4F2 and two cell lines were tested for unmodified
cytosines after bisulphite modification, which would
indicate methylation of these loci. Although, one of the
cell lines (SK-N-BE) was methylated at several CpG sites of
the  POU4F2  promoter, none of the primary tumours
showed any remaining cytosines, and there were conse-
quently no differences in promoter methylation between
favourables and unfavourables (Figure 4).
CNTNAP2 copy number analysis
In the current study, the mRNA level of CNTNAP2 was 5
times lower in unfavourables versus favourable tumours.
This could indicate an inactivation by mutation or entire/
partial deletion of the gene in unfavourable tumours.
CNTNAP2 is one of the largest genes in the genome, and
is located in a fragile site on 7q35-36. In order to find an
explanation for the low expression in unfavourable neu-
roblastoma tumours, we scrutinized SNP microarray data
from six unfavourable tumours (see Table 1) to search for
deletions and other copy number aberrations of the
CNTNAP2 gene (see additional file 2). Two tumour spec-
imens (11E1, 9R9) showed gain of the whole chromo-
some 7q arm, but none of them showed deletions in the
7q35-36 region. Thus, the low expression of CNTNAP2
seen in these tumours does not seem to be caused by large
genomic deletions, but an inactivation may still be caused
by other mutational events.
Discussion
Neuroblastoma is with its highly divergent clinical and
genetic manifestations an elusive disease to study. Some
characteristic genetic features have been found but none
of them solely explains the variance in tumour behaviour
and responsiveness to treatment. In the current study we
performed a large-scale real-time PCR (TLDA) expression
analysis to guide our selection of genes that are seemingly
downregulated in unfavourable tumours, i.e. potential
tumour suppressor genes. The natural approach would be
to compare tumour tissue to its non-cancerous counter-
part. However, since human normal embryonal sympa-
thetic nervous system cells are not available for research
studies, we chose to compare aggressive (unfavourable) to
benign (favourable) tumours originating from the same
type of precursor cells. A two step verification strategy was
used, in which we started out by analysing the expression
levels of 89 candidate transcripts, which were subse-
quently narrowed to 12 strong candidates for neuroblast-
oma progression. By TLDA analysis we were able to
confirm the differential expression of 81 out of 87 tran-
scripts seen in our microarray study. Fourteen of these
transcripts have been suggested as differentially expressed
in NB tumours in several independent research studies
[14,15,18,31-36] (Table 2). To further strengthen our
results we chose to perform a follow up study using a new
set of tumours. In this second verification group we could
confirm a lower gene expression in seven out of 12 genes
(Table 3, Figure 3). Since the majority (9 out of 15) of
unfavourable tumours show MNA, one could speculate
that many of the differentially expressed transcripts could
be part of the MYCN downstream signalling pathway and
the lower expression would be merely an effect of MNA.
However, a multiple linear regression of the second verifi-
cation group showed that "group" (UF versus F) remained
the strongest predictor of differential expression com-
pared to "MNA", hence the downregulation of the seven
transcripts seems independent to MNA. Moreover, the 89
genes selected for the first verification round are not
included in MYC curated genesets from Molecular Signa-
ture Database (Broad Institute, http://
www.broad.mit.edu), seemingly the majority of differen-
tially expressed transcripts verified in this study are not
part of the MYCN downstream signalling network.
In this study the differential expression of POU4F2 was
dramatic, as high as 1500 times difference in the first stud-
ied group of tumours. The large variance of expression was
an effect of a complete depletion of the transcript in sev-
eral unfavourable tumours in combination with a very
high expression in some favourable tumours (Figure 3).
BSP sequencing of the POU4F2 promoter Figure 4
BSP sequencing of the POU4F2 promoter. Cell-line SK-
N-BE shows methylation of CpG sites in the POU4F2 pro-
moter. Cytosines (blue peaks) marked with arrows, are mod-
ified into thymidines (red peaks) if not methylated. Cell-line 
SK-N-BE is compared to unmethylated primary tumour 9R9.BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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POU4F2 has been shown to be essential for the develop-
ment of retinal ganglion cells (RGC) [37] and has also
been suggested to play an important role for a number of
processes including proliferation and invasiveness
[38,39], and development of different forms of malignan-
cies. POU4F2 is a multi-functional protein shown to affect
cell cycle protein [40,41], and to interact with several can-
cer-realted genes such as BRCA1 and TP53 [42,43]. Deple-
tion of POU4F2 has been shown to make cells resistant to
apoptosis, indicating a tumour suppressor function [43].
In a recent study, the POU4F2 transcript has actually, in
contrary to our results, been found to be expressed at a
higher level in primary tumours of higher stages, espe-
cially in stage 3 tumours correlating negatively with MNA
[41]. On the other hand, the whole genome expression
study of Wang and colleagues support our findings that
POU4F2  show high expression in favourable tumours
[15] and so does Albino et al. [34]. The POU4F2 or BRN-
3B gene encodes a class IV POU (Pit-1, Oct1/2 and Unc-
86) transcription factor mapped to 4q31.22. The POU4F2
gene is highly evolutionary conserved and show a high
content of CpG sites indicating that the gene could be reg-
ulated by methylation (Figure 2). Moreover, the expres-
sion of POU4F2 gene is activated by the by the Wilms'
tumour suppressor protein Wt1 [28] and has also been
shown to have a highly conserved 3' UTR which through
miRNA activity regulates the mRNA levels post-transcrip-
tionally [39]. However, the mutation screeening of
POU4F2 showed no apparent pathogenic alterations in
the coding and regulatory parts of the gene, nor did we
find any methylated CpG sites in the primary tumours,
suggesting that the lower gene expression seen in UF
tumours are not due to genetic alterations or DNA meth-
ylation. The only sample showing a few methylated CpG
sites was the NB cell-line SK-N-BE (Figure 4). This result
was in accordance to our previous observations where the
expression levels of POU4F2 were up-regulated upon de-
methylation of this cell-line.
Altogether, a differential expression of POU4F2 has been
observed in several individual studies, which indicates an
important function of this transcription factor during the
process of NB tumour progression. Whether it functions
as a survival factor or as a silenced tumour suppressor in
these cases remain to be solved.
After the second verification round, CNTNAP2 showed
the largest change in expression between groups of NB.
CNTNAP2, or CASPR2 is one of the largest genes of the
human genome, spanning over 2 Mb in size, encoding a
protein localized in the complexes forming around spe-
cific K+ channels of myelinated axons [44]. Its location in
the genome, 7q36, has been identified as a common frag-
ile site (CFS), a large region more prone to show genomic
instability with frequent deletions and other alterations
[45]. The CFS genes have, both in in vitro and in vivo stud-
ies been suggested to be involved in development of can-
cer where they lose their function as tumour suppressor
genes. McAvoy and colleagues found that CNTNAP2 was
inactivated in brain tumours [19], which together with
our findings support a tumour suppressor function of
CNTNAP2 in neural cells. As CNTNAP2 gene is located in
a CFS-site 7q35-36 it is not unlikely that the inactivation
seen in unfavourable NB tumours is caused by entire or
partial gene deletions at DNA level. However, copy
number analysis of more than 300 SNP's covering
CNTNAP2 showed that both alleles were retained in the
genome in the six analysed tumours, and gene deletions
are not likely to be the cause of the low expression seen in
unfavourable tumours (see additional file 2). It is still pos-
sible that other genetic alterations may have affected the
expression levels, and further studies of this gene are
needed.
Also, CACNA2D3 and TFAP2B showed high differential
expression between groups in the second verification
round. CACNA2D3 encodes a calcium channel protein
located on 3p22, a locus which is lost in more than half of
the most aggressive NB cases especially in the absence of
MNA [46]. A difference in expression between favourable
and unfavourable NB has previously been observed by
dePreter et al. [31]. Also, CACNA2D3 has been suggested
to be a tumour suppressor gene in esophageal squamous
cell carcinoma and has recently been found to be a poor
prognostic factor in gastric cancer [47]. TFAP2B is one of
the four members of the AP-class of transcription factors,
plays a role in the retinoic acid-induced differentiation of
neural crest cells, and is involved in the development of
the kidney. Ebauer et al. has suggested that TFAP2B is the
direct target gene of PAX3/FKHR fusion gene in alveolar
rhabdomyosarcoma and responsible for the anti-apop-
totic function of PAX3/FKHR [48]. Also, TFAP2B  was
recently suggested to be one of the genes discriminating
between stroma-rich and stroma-poor neuroblastic
tumours, in an approach similar to this study [34].
Conclusion
In summary, several of the genes studied, particularly
CACNA2D3, CNTNAP2, and TFAP2B, show a subgroup-
specific expression pattern and could play a role in the
development or maintenance of NB cancer cells. Apart
from the noradrenergic pathway genes (DBH,  DCC,
GATA2, GATA3, PHOX2A, PHOX2B, SLC6A2, SLC18A1,
and TH) [23], several previously reported genes have in
this study been verified as differentially expressed genes,
i.e. CACNA2D3,  DPYSL3,  GNB1,  POU4F2,  RAPGEF6,
SLC35E2, and TFAP2B (Table 2 and 3) [14,15,18,32-37].
Down-regulation of these transcripts is a potential marker
of tumour progression. Further routes of investigation are
to analyse whether these changes in expression can be
considered essential for the tumour progression and if
these genes are deregulated because of alterations affect-BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
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ing them alone or if they are parts of affected pathways.
Another issue is the possibility that the apparently down-
regulated tumour suppressor genes in unfavourable
tumours are in fact survival genes that are up-regulated in
favourable ones, and further experimental studies are
needed to confirm their tumour suppressor function.
In conclusion, this study verifies several differentially
expressed transcripts that might have a potential clinical
implication when it comes to increasing the accuracy of
grouping and sub-grouping patients with NB, and guide
for better treatment strategies. Further studies of these
transcripts role in cellular networks will hopefully con-
tribute to an even more detailed picture of the NB
tumourigenesis and increase the understanding about this
complex disease.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KT carried out the real-time PCR and sequencing experi-
ments, analyzed results and drafted the manuscript. FA
formulated the study design, performed the microarray
and TLDA analysis, supervised the calculations and inter-
pretations of results, and revised the manuscript. AB con-
tributed to the DNA copy number analysis and revised the
manuscript. HC designed the methylation study and car-
ried out the bisulphite modification. SN performed statis-
tical analysis. TM provided DNA copy number data and
performed the SNP microarray analysis, and provided
clinical stages. PK provided clinical input on tumour clas-
sification and overall survival. All authors read and
approved the final manuscript.
Additional material
Acknowledgements
We are grateful to Rose-Marie Sjöberg who organized and provided 
tumour material and DNA samples for this study. We would like to thank 
the Genomics Core Facility resource unit at the University of Gothenburg 
for help and access to the .ABI PRISM® 7900HT Sequence Detection Sys-
tem. This work was supported by grants from the Swedish Medical Council, 
the Children's Cancer Foundation, the King Gustav V Jubilee Clinic Cancer 
Research Foundation, the Assar Gabrielsson Foundation, the Wilhelm and 
Martina Lundgren Research Foundation, and the Nilsson-Ehle Foundation.
References
1. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma.  Lan-
cet 2007, 369(9579):2106-2120.
2. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castel-
berry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al.: Revi-
sions of the international criteria for neuroblastoma
diagnosis, staging, and response to treatment.  J Clin Oncol
1993, 11(8):1466-1477.
3. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW: Prognos-
tic factor in neuroblastoma.  Cancer 1987, 59(11):1853-1859.
4. Breslow N, McCann B: Statistical estimation of prognosis for
children with neuroblastoma.  Cancer Res 1971,
31(12):2098-2103.
5. Brodeur GM: Neuroblastoma: biological insights into a clinical
enigma.  Nat Rev Cancer 2003, 3(3):203-216.
6. Maris JM: The biologic basis for neuroblastoma heterogeneity
and risk stratification.  Curr Opin Pediatr 2005, 17(1):7-13.
7. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF,
Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al.: Identification of
ALK as a major familial neuroblastoma predisposition gene.
Nature 2008, 455(7215):883-4.
8. Carén H, Abel F, Kogner P, Martinsson T: High incidence of DNA
mutations and gene amplifications of the ALK gene in
advanced sporadic neuroblastoma tumours.  Biochem J 2008,
416(2):153-9.
9. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J,
Ahn Y, Zhou W, London WB, McGrady P, et al.: Activating muta-
tions in ALK provide a therapeutic target in neuroblastoma.
Nature 2008, 455(7215):975-8.
10. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda
M, Kikuchi A, Igarashi T, et al.: Oncogenic mutations of ALK
kinase in neuroblastoma.  Nature 2008, 455(7215):971-4.
11. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L,
Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et
al.: Somatic and germline activating mutations of the ALK
kinase receptor in neuroblastoma.  Nature 2008,
455(7215):967-70.
12. Maris JM, Matthay KK: Molecular biology of neuroblastoma.  J
Clin Oncol 1999, 17(7):2264-2279.
13. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F,
Berthold F, Schwab M, Antonescu CR, Peterson C, et al.: Classifica-
tion and diagnostic prediction of cancers using gene expres-
sion profiling and artificial neural networks.  Nat Med 2001,
7(6):673-679.
14. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H,
Warnat P, Ernestus K, Hero B, Berthold F: Differential expression
of neuronal genes defines subtypes of disseminated neurob-
lastoma with favorable and unfavorable outcome.  Clin Cancer
Res 2006, 12(17):5118-5128.
15. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E,
Jagannathan J, Shusterman S, Bansal M, et al.: Integrative genomics
identifies distinct molecular classes of neuroblastoma and
shows that multiple genes are targeted by regional altera-
tions in DNA copy number.  Cancer Res 2006, 66(12):6050-6062.
16. Abel F, Sjoberg RM, Nilsson S, Kogner P, Martinsson T: Imbalance
of the mitochondrial pro- and anti-apoptotic mediators in
neuroblastoma tumours with unfavourable biology.  Eur J Can-
cer 2005, 41(4):635-646.
17. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama
T: Expression profiling of favorable and unfavorable neurob-
lastomas.  Pediatr Surg Int 2004, 20(1):33-38.
Additional file 1
Microarray versus QPCR: a correlation comparison of technical plat-
forms. Histogram over the Pearson correlation coefficients between micro-
array and QPCR expression levels of 87 genes analysed in 5 cases 
(technical replicates). The correlation calculation is based upon log2 
expression values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8794-2-53-S1.pdf]
Additional file 2
Copy number analysis of CNTNAP2. 250 K SNP microarray data 
(Nsp) from six unfavourable NB tumours were scrutinized for entire or 
partial deletions in the 7q35-36 region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8794-2-53-S2.pdf]BMC Medical Genomics 2009, 2:53 http://www.biomedcentral.com/1755-8794/2/53
Page 13 of 13
(page number not for citation purposes)
18. McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breat-
nach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM, et al.:
Oligonucleotide microarray analysis of gene expression in
neuroblastoma displaying loss of chromosome 11q.  Carcino-
genesis 2004, 25(9):1599-1609.
19. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR,
Kosari F, Perez DS, Zhu Y, James CD, Smith DI: Non-random inac-
tivation of large common fragile site genes in different can-
cers.  Cytogenet Genome Res 2007, 118(2–4):260-269.
20. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T,
Nakagawara A, Ushijima T: CpG island methylator phenotype is
a strong determinant of poor prognosis in neuroblastomas.
Cancer Res 2005, 65(3):828-834.
21. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Allemanni G,
Bonassi S, Tonini GP, Romani M: Distinct CpG methylation pro-
files characterize different clinical groups of neuroblastic
tumors.  Oncogene 2005, 24(36):5619-5628.
22. Wilzen A, Nilsson S, Sjoberg RM, Martinsson T, Abel F: The Phox2
pathway is differentially expressed in neuroblastoma
tumors, but no mutations could be found in the candidate
tumor suppressor gene PHOX2A.  Int J Oncol 2009,
34(3):697-705.
23. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Hol-
mes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, et al.:
INRG Task Force. The International Neuroblastoma Risk
Group (INRG) Staging System: An INRG Task Force Report.
J Clin Oncol 2009, 27(2):298-303.
24. Martinsson T, Sjoberg RM, Hedborg F, Kogner P: Deletion of chro-
mosome 1p loci and microsatellite instability in neuroblast-
omas analyzed with short-tandem repeat polymorphisms.
Cancer Res 1995, 55(23):5681-5686.
25. Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F,
Kogner P: Delimitation of a critical tumour suppressor region
at distal 1p in neuroblastoma tumours.  Eur J Cancer 1997,
33(12):1997-2001.
26. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, Abrahamsson
J, Kogner P, Martinsson T: High-resolution array copy number
analyses for detection of deletion, gain, amplification and
copy-neutral LOH in primary neuroblastoma tumors: four
cases of homozygous deletions of the CDKN2A gene.  BMC
Genomics 2008, 9:353.
27. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F: Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multi-
ple internal control genes.  Genome Biol 2002,
3(7):RESEARCH0034.
28. Wagner KD, Wagner N, Schley G, Theres H, Scholz H: The Wilms'
tumor suppressor Wt1 encodes a transcriptional activator
of the class IV POU-domain factor Pou4f2 (Brn-3b).  Gene
2003, 305(2):217-223.
29. Takai D, Jones PA: Comprehensive analysis of CpG islands in
human chromosomes 21 and 22.  Proc Natl Acad Sci USA 2002,
99(6):3740-3745.
30. Tusnady GE, Simon I, Varadi A, Aranyi T: BiSearch: primer-design
and search tool for PCR on bisulfite-treated genomes.  Nucleic
Acids Res 2005, 33(1):e9.
31. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S,
Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, et al.: Human
fetal neuroblast and neuroblastoma transcriptome analysis
confirms neuroblast origin and highlights neuroblastoma
candidate genes.  Genome Biol 2006, 7(9):R84.
32. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata
T, Kubo H, Goto T, Yamada S, et al.: Expression profiling using a
tumor-specific cDNA microarray predicts the prognosis of
intermediate risk neuroblastomas.  Cancer Cell 2005,
7(4):337-350.
33. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B,
Hero B, Eils R, Schwab M, Berthold F, et al.: Classification of neu-
roblastoma patients by published gene-expression markers
reveals a low sensitivity for unfavorable courses of MYCN
non-amplified disease.  Cancer Lett 2007, 250(2):250-267.
34. Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C,
Cavazzana A, Stigliani S, Bonassi S, Tonini GP: Identification of low
intratumoral gene expression heterogeneity in neuroblastic
tumors by genome-wide expression analysis and game the-
ory.  Cancer 2008, 113(6):1412-1422.
35. Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B:
Cross-study analysis of gene expression data for intermedi-
ate neuroblastoma identifies two biological subtypes.  BMC
Cancer 2007, 7:89.
36. Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H, Brodeur GM:
Expression of Apo-3 and Apo-3L in primitive neuroectoder-
mal tumours of the central and peripheral nervous system.
Eur J Cancer 2002, 38(1):92-98.
37. Xiang M: Requirement for Brn-3b in early differentiation of
postmitotic retinal ganglion cell precursors.  Dev Biol 1998,
197(2):155-169.
38. Irshad S, Pedley RB, Anderson J, Latchman DS, Budhram-Mahadeo V:
The Brn-3b transcription factor regulates the growth,
behavior, and invasiveness of human neuroblastoma cells in
vitro and in vivo.  J Biol Chem 2004, 279(20):21617-21627.
39. Calissano M, Diss JK, Latchman DS: Post-transcriptional regula-
tion of the Brn-3b transcription factor in differentiating neu-
roblastoma cells.  FEBS Lett 2007, 581(13):2490-2496.
40. Zhu T, Sukumar S: Coupling the transcriptional regulatory
action of Brn-3b to the cell cycle clock.  Cancer Biol Ther 2004,
3(3):324-325.
41. Budhram-Mahadeo VS, Irshad S, Bowen S, Lee SA, Samady L, Tonini
GP, Latchman DS: Proliferation-associated Brn-3b transcrip-
tion factor can activate cyclin D1 expression in neuroblast-
oma and breast cancer cells.  Oncogene 2008, 27(1):145-154.
42. Budhram-Mahadeo V, Ndisang D, Ward T, Weber BL, Latchman DS:
The Brn-3b POU family transcription factor represses
expression of the BRCA-1 anti-oncogene in breast cancer
cells.  Oncogene 1999, 18(48):6684-6691.
43. Budhram-Mahadeo VS, Bowen S, Lee S, Perez-Sanchez C, Ensor E,
Morris PJ, Latchman DS: Brn-3b enhances the pro-apoptotic
effects of p53 but not its induction of cell cycle arrest by
cooperating in trans-activation of bax expression.  Nucleic
Acids Res 2006, 34(22):6640-6652.
44. Poliak S, Gollan L, Salomon D, Berglund EO, Ohara R, Ranscht B,
Peles E: Localization of Caspr2 in myelinated nerves depends
on axon-glia interactions and the generation of barriers
along the axon.  J Neurosci 2001, 21(19):7568-7575.
45. Smith DI, Zhu Y, McAvoy S, Kuhn R: Common fragile sites,
extremely large genes, neural development and cancer.  Can-
cer Lett 2006, 232(1):48-57.
46. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jag-
annathan J, Bhambhani K, Winter C, Maris JM: Neuroblastomas
have distinct genomic DNA profiles that predict clinical phe-
notype and regional gene expression.  Genes Chromosomes Can-
cer 2007, 46(10):936-949.
47. Wanajo A, Sasaki A, Nagasaki H, Shimada S, Otsubo T, Owaki S,
Shimizu Y, Eishi Y, Kojima K, Nakajima Y, et al.: Methylation of the
calcium channel-related gene, CACNA2D3, is frequent and
a poor prognostic factor in gastric cancer.  Gastroenterology
2008, 135(2):580-590.
48. Ebauer M, Wachtel M, Niggli FK, Schafer BW: Comparative
expression profiling identifies an in vivo target gene signa-
ture with TFAP2B as a mediator of the survival function of
PAX3/FKHR.  Oncogene 2007, 26(51):7267-7281.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1755-8794/2/53/prepub